Table 1B.
Baseline characteristics, for additional variables, of participants assigned to the DIAMOND programme (n = 21) or usual care (n = 12). Values are mean (standard deviation) unless stated otherwise
| Outcome measure | Intervention group (mean ± SD) | Control group (mean ± SD) |
|---|---|---|
| Glycaemic control | ||
| Fasting glucose, mmol/L | 10.0 (3.4) | 8.3 (1.6) |
| Fasting insulin, pmol/L | 95.1 (28.6) | 92.6 (52.2) |
| HOMA | ||
| HOMA‐%B | 49.3 (26.9) | 56.2 (27.88) |
| HOMA‐%S | 51.7 (14.3) | 63.7 (24.7) |
| HOMA‐IR | 2.1 (0.6) | 1.9 (1.1) |
| Lipid profile | ||
| Total cholesterol, mmol/L | 4.3 (1.0) | 4.3 (1.0) |
| HDL, mmol/L | 1.1 (0.2) | 1.3 (0.3) |
| Triglycerides, mmol/L | 2.1 (1.2) | 1.7 (0.6) |
| Non‐HDL cholesterol, mmol/L | 2.4 (1.0) | 2.3 (0.9) |
| Total cholesterol: HDL ratio | 3.8 (1.0) | 3.5 (1.1) |
| Liver function tests | ||
| Bilirubin, μmol/L | 15.6 (7.7) | 14.3 (6.1) |
| AST, IU/L | 27.4 (12.0) | 23.6 (9.4) |
| ALT, IU/L | 34.1 (22.0) | 28.8 (19.6) |
| ALP, IU/L | 77.4 (23.1) | 83.9 (18.5) |
| Albumin, g/L | 39.1 (2.0) | 39.3 (2.4) |
| GGT, IU/L | 50.2 (26.8) | 59.8 (90.0) |
| AST:ALT ratio | 1.0 (0.3) | 0.9 (0.2) |
| QRISK | 28.2 (15.6) | 20.8 (10.1) |
| PAID score | 14.4 (13.4) | 20.7 (15.8) |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transferase; HDL, high density lipoprotein; HOMA, homeostatic model assessment; HOMA‐IR, insulin resistance; HOMA‐β, steady state β cell function; HOMA‐S, insulin sensitivity; PAID, Problem Areas In Diabetes score; QRISK, calculated 10‐year risk of cardiovascular disease.